C4 Therapeutics, Inc. - stock earnings
CCCC Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 2, 2024 BeforeMarket | - / -0.3585000000 | - | - / 8.3 million | - |
CCCC Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -34.8 million USD | 3.3 million USD |
| 2023Q3 | -27.0 million USD | 11.1 million USD |
| 2023Q2 | -35.9 million USD | 2.7 million USD |
| 2023Q1 | -33.9 million USD | 3.8 million USD |
| 2022Q4 | -36.1 million USD | 2.9 million USD |
| 2022Q3 | -31.4 million USD | 6.8 million USD |
| 2022Q2 | -27.4 million USD | 13.8 million USD |
| 2022Q1 | -31.9 million USD | 7.7 million USD |
| 2021Q4 | -15.7 million USD | 20.1 million USD |
| 2021Q3 | -24.7 million USD | 8.5 million USD |
| 2021Q2 | -22.6 million USD | 9.8 million USD |
| 2021Q1 | -21.0 million USD | 7.4 million USD |
| 2020Q4 | -21.8 million USD | 8.3 million USD |
| 2020Q3 | -21.8 million USD | 8.4 million USD |
| 2020Q2 | -10.8 million USD | 9.7 million USD |
| 2020Q1 | -11.9 million USD | 6.8 million USD |
| 2019Q4 | -10.0 million USD | 8.2 million USD |
| 2019Q3 | -10.1 million USD | 5.4 million USD |
CCCC Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -132.5 million USD | 20.8 million USD |
| 2022 | -126.5 million USD | 31.1 million USD |
| 2021 | -86.0 million USD | 45.8 million USD |
| 2020 | -66.3 million USD | 33.2 million USD |
| 2019 | -34.1 million USD | 21.4 million USD |
| 2018 | -15.7 million USD | 19.4 million USD |
CCCC
Price: $6.74
52 week price:
Earnings Per Share: -2.67 USD
P/E Ratio: -1.95
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 914600
Market Capitalization: 515.9 million